What is Catalyst Pharmaceutical Inc.'s earnings per share (EPS)?

Catalyst Pharmaceutical Inc. (CPRX) reported diluted earnings per share of $1.68 for fiscal year 2025. This represents a 28.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Catalyst Pharmaceutical Inc. (CPRX) Financials

CPRX

Trailing 12 months to March 31, 2026

Revenue $597.0M +11.7% YoY

Net Income $221.3M +12.1% YoY

EPS (Diluted) $1.74 +10.8% YoY

Free Cash Flow $208.1M -22.2% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported May 11, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2026, filed May 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CPRX SEC filings page.

Catalyst Pharmaceutical Inc. (CPRX) reported $597.0M in revenue over the twelve months to Mar 31, 2026, up 11.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CPRX FY2025 2026-08-29

Operating leverage is widening margins and producing cash, while rising receivables—not capital spending—absorb more of the latest growth.

Revenue grew 19.8% while operating margin widened, showing growth reached profit more efficiently. Gross margin edged down from 86.0% to 85.2%, so the improvement came below gross profit rather than from richer product-level economics.

Net income reached $214M in FY2025 while operating cash flow was $209M, narrowing the usual gap between accounting profit and cash generation. Free cash flow nearly matched operating cash flow because capital spending was minimal, so the weaker cash margin appears tied to receivables absorbing growth rather than heavy reinvestment.

A 6.1x current ratio alongside a 0.2x debt-to-equity ratio signals substantial short-term balance-sheet capacity without meaningful reliance on debt. Liabilities remained modest relative to assets, while retained earnings increased, indicating expansion has been financed largely through internally accumulated equity rather than borrowing.

Financial Health Signals

Financial Health Score 89/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Catalyst Pharmaceutical Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Catalyst Pharmaceutical Inc. has an operating margin of 43.8%, meaning the company retains $44 of operating profit per $100 of revenue. This strong profitability earns a score of 90/100, reflecting efficient cost management and pricing power. This is up from 39.7% the prior year.

Growth

Catalyst Pharmaceutical Inc.'s revenue surged 19.8% year-over-year to $589.0M, reflecting rapid business expansion. This strong growth earns a score of 83/100.

Leverage

Catalyst Pharmaceutical Inc. carries a low D/E ratio of 0.16, meaning only $0.16 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 78/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 6.08, Catalyst Pharmaceutical Inc. holds $6.08 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 94/100.

Cash Flow

Catalyst Pharmaceutical Inc. converts 35.4% of revenue into free cash flow ($208.6M). This strong cash generation earns a score of 97/100.

Returns

Catalyst Pharmaceutical Inc. earns a strong 22.5% return on equity (ROE), meaning it generates $22 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 93/100. This is unchanged from the prior year.

Altman Z-Score Safe

18.17

Catalyst Pharmaceutical Inc. scores 18.17, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($3.9B) relative to total liabilities ($149.7M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

Catalyst Pharmaceutical Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Mixed

0.97x

For every $1 of reported earnings, Catalyst Pharmaceutical Inc. generates $0.97 in operating cash flow ($208.7M OCF vs $214.3M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$149.4M

YoY+5.6%

QoQ-2.1%

5Y CAGR+37.7%

Catalyst Pharmaceutical Inc. generated $149.4M in revenue in Q1 2026. This represents an increase of 5.6% from the same quarter a year earlier. Against the prior quarter it is down 2.1%.

EBITDA

$83.0M

YoY+14.0%

QoQ+16.3%

5Y CAGR+53.0%

Catalyst Pharmaceutical Inc.'s EBITDA was $83.0M in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 14.0% from the same quarter a year earlier. Against the prior quarter it is up 16.3%.

Net Income

$63.7M

YoY+12.3%

QoQ+20.9%

5Y CAGR+52.8%

Catalyst Pharmaceutical Inc. reported $63.7M in net income in Q1 2026. This represents an increase of 12.3% from the same quarter a year earlier. Against the prior quarter it is up 20.9%.

EPS (Diluted)

$0.50

YoY+11.1%

QoQ+22.0%

5Y CAGR+48.2%

Catalyst Pharmaceutical Inc. earned $0.50 per diluted share (EPS) in Q1 2026. This represents an increase of 11.1% from the same quarter a year earlier. Against the prior quarter it is up 22.0%.

Cash & Balance Sheet

Free Cash Flow

$59.6M

YoY-0.8%

QoQ+32.8%

Catalyst Pharmaceutical Inc. generated $59.6M in free cash flow in Q1 2026, representing cash available after capex. This represents a decrease of 0.8% from the same quarter a year earlier. Against the prior quarter it is up 32.8%.

Cash & Debt

$755.9M

YoY+30.2%

QoQ+6.6%

5Y CAGR+42.8%

10Y CAGR+42.3%

Catalyst Pharmaceutical Inc. held $755.9M in cash as of Q1 2026; long-term debt is not reported for that period.

Shares Outstanding

122M

YoY+0.3%

QoQ+0.2%

5Y CAGR+3.4%

10Y CAGR+4.0%

Catalyst Pharmaceutical Inc. had 122M shares outstanding in Q1 2026. This represents an increase of 0.3% from the same quarter a year earlier. Against the prior quarter it is up 0.2%.

Dividends Per Share

Not reported for Q1 2026.

Margins & Returns

Gross Margin

90.3%

YoY+3.0pp

QoQ+7.4pp

5Y change+5.8pp

Catalyst Pharmaceutical Inc.'s gross margin was 90.3% in Q1 2026, indicating the percentage of revenue retained after direct costs. This is up 3.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.4 percentage points.

Operating Margin

49.0%

YoY+4.2pp

QoQ+8.5pp

5Y change+16.6pp

Catalyst Pharmaceutical Inc.'s operating margin was 49.0% in Q1 2026, reflecting core business profitability. This is up 4.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 8.5 percentage points.

Net Margin

42.7%

YoY+2.5pp

QoQ+8.1pp

5Y change+17.3pp

Catalyst Pharmaceutical Inc.'s net profit margin was 42.7% in Q1 2026, showing the share of revenue converted to profit. This is up 2.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 8.1 percentage points.

Return on Equity

6.3%

YoY-0.9pp

QoQ+0.8pp

5Y change+2.0pp

10Y change+16.9pp

Catalyst Pharmaceutical Inc.'s ROE was 6.3% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is down 0.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.8 percentage points.

Capital Allocation

R&D Spending

$2.7M

YoY-31.5%

QoQ+47.3%

5Y CAGR-2.4%

Catalyst Pharmaceutical Inc. invested $2.7M in research and development in Q1 2026. This represents a decrease of 31.5% from the same quarter a year earlier. Against the prior quarter it is up 47.3%.

Share Buybacks

$14.6M

Catalyst Pharmaceutical Inc. spent $14.6M on share buybacks in Q1 2026, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

$27K

QoQ-15.6%

Catalyst Pharmaceutical Inc. invested $27K in capex in Q1 2026, funding long-term assets and infrastructure. Against the prior quarter it is down 15.6%.

CPRX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CPRX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$597.0M	$589.0M+19.8%	$491.7M+23.5%	$398.2M+85.9%	$214.2M+52.1%	$140.8M+18.3%	$119.1M+16.4%	$102.3M+20361.3%	$500K	$0	$0	$0	$0	$0	$0	N/A
Cost of Revenue	$83.8M	$87.3M+26.7%	$68.8M+32.5%	$52.0M+51.1%	$34.4M+57.2%	$21.9M+28.4%	$17.0M+15.4%	$14.8M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	$513.1M	$501.7M+18.6%	$422.9M+22.1%	$346.2M+92.6%	$179.8M+51.2%	$118.9M+16.6%	$102.0M+16.5%	$87.5M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$11.5M	$12.7M+0.5%	$12.6M-86.4%	$93.2M+370.7%	$19.8M+16.8%	$16.9M+2.7%	$16.5M-12.5%	$18.8M-5.4%	$19.9M+75.1%	$11.4M0.0%	$11.4M-3.7%	$11.8M+16.6%	$10.1M+25.0%	$8.1M+204.4%	$2.7M-21.4%	$3.4M
SG&A Expenses	$196.2M	$193.8M+9.0%	$177.7M+32.9%	$133.7M+134.2%	$57.1M+15.0%	$49.6M+12.2%	$44.2M+19.9%	$36.9M+132.3%	$15.9M+117.3%	$7.3M-7.7%	$7.9M-8.0%	$8.6M+92.2%	$4.5M+102.0%	$2.2M-13.5%	$2.6M-5.1%	$2.7M
Operating Income	$267.6M	$257.8M+32.1%	$195.1M+124.8%	$86.8M-14.8%	$101.8M+94.4%	$52.4M+26.8%	$41.3M+29.8%	$31.8M+190.2%	-$35.3M-88.9%	-$18.7M+3.1%	-$19.3M+5.5%	-$20.4M-39.8%	-$14.6M-41.5%	-$10.3M-97.5%	-$5.2M+14.2%	-$6.1M
EBITDA	N/A	$295.7M+26.9%	$232.9M+94.6%	$119.7M+16.1%	$103.1M+96.0%	$52.6M+27.0%	$41.4M+29.9%	$31.9M+190.4%	-$35.3M-89.2%	-$18.6M+3.1%	-$19.2M+5.5%	-$20.4M-39.8%	-$14.6M-41.6%	-$10.3M-97.5%	-$5.2M+13.7%	-$6.0M
Income Tax	$75.1M	$69.2M+32.1%	$52.4M+126.7%	$23.1M+6.8%	$21.6M+64.1%	$13.2M+139.8%	-$33.1M-2257.3%	$1.5M	$0	$0	$0	$0	$0	$0	$0	N/A
Net Income	$221.3M	$214.3M+30.8%	$163.9M+129.5%	$71.4M-14.0%	$83.1M+110.4%	$39.5M-47.3%	$75.0M+135.2%	$31.9M+193.7%	-$34.0M-84.7%	-$18.4M-1.9%	-$18.1M+10.7%	-$20.2M-30.5%	-$15.5M-27.6%	-$12.2M-198.2%	-$4.1M+36.2%	-$6.4M
EPS (Basic)	N/A	$1.75+26.8%	$1.38+106.0%	$0.67-16.3%	$0.80+110.5%	$0.38-47.2%	$0.72+132.3%	$0.31+193.9%	-$0.33	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	$1.74	$1.68+28.2%	$1.31+107.9%	$0.63-16.0%	$0.75+102.7%	$0.37-47.9%	$0.71+136.7%	$0.30+190.9%	-$0.33	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	127M+1.9%	125M+9.8%	114M+2.1%	111M+3.3%	108M+1.5%	106M+0.2%	106M+3.3%	103M	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Revenue	$149.4M+5.6%	$152.6M+7.6%	$148.4M+15.3%	$146.6M+19.4%	$141.4M+43.6%	$141.8M+28.3%	$128.7M+25.3%	$122.7M+23.2%
Cost of Revenue	$14.5M-19.2%	$26.1M+20.5%	$22.7M+17.5%	$20.6M+33.8%	$17.9M+43.1%	$21.6M+36.9%	$19.3M+36.1%	$15.4M+27.9%
Gross Profit	$134.9M+9.2%	$126.5M+5.3%	$125.7M+14.9%	$125.9M+17.4%	$123.5M+43.6%	$120.2M+26.8%	$109.4M+23.6%	$107.3M+22.6%
R&D Expenses	$2.7M-31.5%	$1.8M-52.4%	$2.7M-19.1%	$4.4M+46.0%	$3.9M+50.6%	$3.8M+92.6%	$3.3M-96.1%	$3.0M-24.5%
SG&A Expenses	$49.3M+5.1%	$53.4M+20.9%	$47.5M+3.5%	$45.9M+12.8%	$46.9M-0.1%	$44.2M+5.1%	$45.9M+36.7%	$40.7M+43.4%
Operating Income	$73.2M+15.6%	$61.8M-1.6%	$66.3M+30.2%	$66.3M+22.2%	$63.4M+133.6%	$62.8M+50.7%	$50.9M+236.9%	$54.2M+16.2%
EBITDA	$83.0M+14.0%	$71.4M-1.3%	$75.7M+25.4%	$75.8M+19.0%	$72.8M+99.2%	$72.3M+42.2%	$60.4M+310.9%	$63.7M+15.2%
Income Tax	$20.5M+40.9%	$19.2M+5.3%	$18.3M+37.0%	$17.2M+14.6%	$14.5M+150.2%	$18.2M+53.8%	$13.3M+283.6%	$15.0M+39.5%
Net Income	$63.7M+12.3%	$52.7M-5.8%	$52.8M+20.3%	$52.1M+27.7%	$56.7M+143.8%	$55.9M+60.5%	$43.9M+242.6%	$40.8M+8.0%
EPS (Basic)	$0.52+10.6%	$0.43-6.5%	$0.43+16.2%	$0.43+22.9%	$0.47+135.0%	$0.46+39.4%	$0.37+227.6%	$0.35-2.8%
EPS (Diluted)	$0.50+11.1%	$0.41-6.8%	$0.42+20.0%	$0.41+24.2%	$0.45+136.8%	$0.44+41.9%	$0.35+220.7%	$0.330.0%
Diluted Shares (Avg)	127M0.0%	N/A	127M+1.3%	128M+2.3%	127M+2.9%	N/A	125M+17.7%	125M+9.7%

Not reported in any period shown, so not listed: Interest Expense.

CPRX Balance Sheet

CPRX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$1.1B+29.7%	$851.4M+81.1%	$470.1M+25.2%	$375.6M+58.0%	$237.8M+23.6%	$192.4M+71.2%	$112.4M+85.9%	$60.4M-29.2%	$85.4M+104.7%	$41.7M-30.6%	$60.1M+36.9%	$43.9M+73.1%	$25.4M+51.1%	$16.8M+168.7%	$6.2M
Current Assets	$894.0M+43.4%	$623.6M+184.3%	$219.3M-31.6%	$320.8M+52.7%	$210.1M+31.9%	$159.2M+43.0%	$111.4M+101.8%	$55.2M-35.2%	$85.2M+105.5%	$41.5M-30.8%	$59.9M+36.7%	$43.8M+73.1%	$25.3M+51.4%	$16.7M+168.6%	$6.2M
Cash & Equivalents	$709.2M+37.0%	$517.6M+276.0%	$137.6M-53.9%	$298.4M+74.0%	$171.4M+31.6%	$130.2M+45.5%	$89.5M+440.6%	$16.6M-71.2%	$57.5M+313.9%	$13.9M-50.8%	$28.2M+210.4%	$9.1M+310.5%	$2.2M+57.2%	$1.4M-76.6%	$6.0M
Short-Term Investments	$0	$0	$0	$0-100.0%	$19.8M+97.4%	$10.0M+100.5%	$5.0M-86.4%	$36.9M+39.2%	$26.5M0.0%	$26.5M+0.3%	$26.4M-0.1%	$26.5M+51.4%	$17.5M+133.0%	$7.5M	$0
Inventory	$37.2M+90.2%	$19.5M+24.9%	$15.6M+129.9%	$6.8M-13.5%	$7.9M+69.2%	$4.7M+137.7%	$2.0M+3393.5%	$56K	$0	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$126.5M+93.2%	$65.5M+22.4%	$53.5M+412.6%	$10.4M+57.7%	$6.6M+10.6%	$6.0M-43.2%	$10.5M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0-100.0%	$5.0M	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$149.7M+21.0%	$123.8M+50.5%	$82.2M+9.3%	$75.2M+142.9%	$31.0M+36.0%	$22.8M-8.0%	$24.7M+156.0%	$9.7M+118.5%	$4.4M+84.5%	$2.4M-48.2%	$4.6M-46.6%	$8.7M+117.8%	$4.0M+83.6%	$2.2M-12.9%	$2.5M
Current Liabilities	$147.2M+21.9%	$120.7M+58.7%	$76.1M+32.1%	$57.6M+112.8%	$27.1M+18.9%	$22.8M-5.6%	$24.1M+153.4%	$9.5M+122.9%	$4.3M+103.7%	$2.1M-39.1%	$3.4M-41.2%	$5.9M+173.6%	$2.1M+29.9%	$1.6M+97.5%	$834K
Non-Current Liabilities	$2.6M-17.5%	$3.1M-49.7%	$6.2M-65.0%	$17.6M+352.5%	$3.9M	$0-100.0%	$648K+318.3%	$155K-1.7%	$157K-48.1%	$303K-74.4%	$1.2M-57.9%	$2.8M+52.9%	$1.8M+253.3%	$520K-68.5%	$1.7M
Total Equity	$954.3M+31.1%	$727.6M+87.6%	$387.9M+29.1%	$300.4M+45.2%	$206.8M+22.0%	$169.6M+93.5%	$87.6M+72.6%	$50.8M-37.3%	$81.0M+106.0%	$39.3M-29.1%	$55.5M+57.4%	$35.2M+64.8%	$21.4M+46.3%	$14.6M+288.8%	$3.8M
Retained Earnings	$474.2M+66.3%	$285.2M+135.1%	$121.3M+143.2%	$49.9M+289.5%	-$26.3M+51.0%	-$53.7M+58.3%	-$128.7M+19.9%	-$160.6M-26.9%	-$126.6M-17.0%	-$108.1M-20.1%	-$90.1M-29.0%	-$69.8M-28.5%	-$54.3M-28.8%	-$42.2M-10.7%	-$38.1M

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Total Assets	$1.1B+26.3%	$1.1B+29.7%	$1.1B+36.2%	$971.9M+37.6%	$908.9M+40.5%	$851.4M+81.1%	$772.0M+86.8%	$706.4M+59.1%
Current Assets	$940.4M+37.1%	$894.0M+43.4%	$852.5M+58.2%	$758.7M+59.9%	$685.7M+69.5%	$623.6M+184.3%	$539.0M+180.7%	$474.4M+96.9%
Cash & Equivalents	$755.9M+30.2%	$709.2M+37.0%	$689.9M+56.0%	$652.8M+73.8%	$580.7M+87.1%	$517.6M+276.0%	$442.3M+265.7%	$375.7M+110.1%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$34.9M+76.6%	$37.2M+90.2%	$28.0M+40.0%	$18.6M+3.5%	$19.8M-0.9%	$19.5M+24.9%	$20.0M+121.5%	$18.0M+67.6%
Accounts Receivable	$130.8M+83.6%	$126.5M+93.2%	$106.4M+82.6%	$65.9M+15.2%	$71.3M+17.8%	$65.5M+22.4%	$58.3M+21.3%	$57.2M+33.6%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$134.9M+17.7%	$149.7M+21.0%	$131.4M+18.3%	$115.9M+18.6%	$114.6M+34.4%	$123.8M+50.5%	$111.1M+71.8%	$97.7M+42.4%
Current Liabilities	$132.4M+18.6%	$147.2M+21.9%	$128.7M+22.1%	$113.0M+22.4%	$111.6M+40.3%	$120.7M+58.7%	$105.4M+82.3%	$92.3M+75.8%
Non-Current Liabilities	$2.5M-14.5%	$2.6M-17.5%	$2.6M-53.8%	$2.9M-46.5%	$2.9M-48.4%	$3.1M-49.7%	$5.7M-17.3%	$5.4M-66.5%
Total Equity	$1.0B+27.5%	$954.3M+31.1%	$920.2M+39.2%	$856.0M+40.6%	$794.3M+41.5%	$727.6M+87.6%	$660.9M+89.6%	$608.7M+62.2%
Retained Earnings	$523.3M+53.1%	$474.2M+66.3%	$446.8M+94.9%	$394.0M+112.6%	$341.9M+136.5%	$285.2M+135.1%	$229.2M+165.2%	$185.3M+58.2%

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

CPRX Cash Flow Statement

CPRX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$208.2M	$208.7M-13.0%	$239.8M+67.0%	$143.6M+23.7%	$116.0M+92.2%	$60.4M+34.1%	$45.0M+30.1%	$34.6M+232.4%	-$26.1M-90.3%	-$13.7M+23.5%	-$18.0M+0.3%	-$18.0M-39.2%	-$12.9M-31.0%	-$9.9M-92.1%	-$5.1M-3.1%	-$5.0M
Depreciation & Amortization	N/A	$37.9M+0.3%	$37.8M+14.9%	$32.9M+2553.8%	$1.2M+545.3%	$192K+108.7%	$92K+67.3%	$55K+44.8%	$38K-16.9%	$46K+5.3%	$43K+25.9%	$34K+29.7%	$27K+18.2%	$22K+106.5%	$11K-74.6%	$43K
Stock-Based Compensation	N/A	$24.8M+11.4%	$22.3M+56.1%	$14.3M+80.2%	$7.9M+30.2%	$6.1M-3.0%	$6.3M+63.7%	$3.8M+7.7%	$3.6M+47.5%	$2.4M+31.1%	$1.8M+15.8%	$1.6M+103.8%	$778K+342.4%	$176K-48.3%	$340K-18.4%	$417K
Capital Expenditures	$85K	$58K-89.6%	$556K+140.7%	$231K+696.6%	$29K-97.2%	$1.0M+9181.8%	$11K-42.1%	$19K-79.4%	$92K	N/A	$96K+309.4%	$23K-59.1%	$57K+507.8%	$9K-82.0%	$52K+1347.0%	$4K
Free Cash Flow	$208.1M	$208.6M-12.8%	$239.3M+66.9%	$143.4M+23.6%	$116.0M+95.5%	$59.4M+31.8%	$45.0M+30.2%	$34.6M+231.8%	-$26.2M	N/A	-$18.1M-0.1%	-$18.0M-38.8%	-$13.0M-31.5%	-$9.9M-90.4%	-$5.2M-4.1%	-$5.0M
Investing Cash Flow	-$85K	-$58K+89.6%	-$556K+99.8%	-$293.5M-3287.1%	$9.2M+183.6%	-$11.0M-119.9%	-$5.0M-113.5%	$37.2M+346.8%	-$15.1M-380973.1%	-$4K	N/A	N/A	N/A	-$7.5M+46.7%	-$14.1M-388288.1%	-$4K
Financing Cash Flow	-$32.9M	-$17.0M-112.1%	$140.7M+1395.6%	-$10.9M-740.9%	$1.7M+120.8%	-$8.1M-1260.0%	$702K-37.1%	$1.1M+280.7%	$293K-99.5%	$57.4M	N/A	N/A	N/A	$18.2M+24.7%	$14.6M+163.1%	$5.5M
Share Buybacks	N/A	$25.3M	$0	$0-100.0%	$6.9M-42.9%	$12.1M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Operating Cash Flow	$59.6M-0.8%	$44.9M-36.7%	$32.4M-55.5%	$71.3M+11.2%	$60.0M+88.1%	$70.9M+27.4%	$72.9M+61.5%	$64.1M+108.5%
Depreciation & Amortization	$9.8M+3.3%	$9.5M+0.8%	$9.4M-0.4%	$9.5M+0.3%	$9.5M+0.3%	$9.5M+3.4%	$9.5M+10.3%	$9.4M+10.1%
Stock-Based Compensation	$6.3M+7.0%	N/A	$5.7M+28.2%	$7.6M+72.3%	$5.8M-29.1%	N/A	$4.4M+16.1%	$4.4M+33.7%
Capital Expenditures	$27K	$32K-63.6%	$0-100.0%	$26K+160.0%	$0-100.0%	$88K-5.4%	$259K+304.7%	$10K
Free Cash Flow	$59.6M-0.8%	$44.9M-36.6%	$32.4M-55.3%	$71.3M+11.1%	$60.0M+89.3%	$70.8M+27.4%	$72.6M+61.1%	$64.1M+108.5%
Investing Cash Flow	-$27K	-$32K+63.6%	$0+100.0%	-$26K-160.0%	$0+100.0%	-$88K+99.8%	-$259K+99.7%	-$10K
Financing Cash Flow	-$12.9M-520.7%	-$25.6M-677.0%	$4.7M+177.9%	$872K-24.6%	$3.1M-97.8%	$4.4M+766.6%	-$6.0M+41.0%	$1.2M+640.7%
Share Buybacks	$14.6M	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Not reported in any period shown, so not listed: Dividends Paid.

CPRX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CPRX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	85.2%-0.8pp	86.0%-1.0pp	87.0%+3.0pp	83.9%-0.5pp	84.5%-1.2pp	85.7%+0.1pp	85.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	43.8%+4.1pp	39.7%+17.9pp	21.8%-25.7pp	47.5%+10.3pp	37.2%+2.5pp	34.7%+3.6pp	31.1%	-7059.0%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	36.4%+3.1pp	33.3%+15.4pp	17.9%-20.9pp	38.8%+10.8pp	28.0%-34.9pp	63.0%+31.8pp	31.2%	-6800.7%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	22.5%-0.1pp	22.5%+4.1pp	18.4%-9.2pp	27.7%+8.6pp	19.1%-25.1pp	44.2%+7.8pp	36.4%+103.3pp	-67.0%-44.2pp	-22.7%+23.2pp	-46.0%-9.5pp	-36.5%+7.5pp	-44.0%+12.8pp	-56.8%-28.9pp	-27.9%+142.1pp	-169.9%
Return on Assets	19.4%+0.2pp	19.3%+4.1pp	15.2%-6.9pp	22.1%+5.5pp	16.6%-22.4pp	39.0%+10.6pp	28.4%+84.6pp	-56.3%-34.7pp	-21.6%+21.8pp	-43.3%-9.7pp	-33.7%+1.7pp	-35.3%+12.6pp	-47.9%-23.6pp	-24.3%+78.0pp	-102.3%
Current Ratio	6.08+0.9x	5.17+2.3x	2.88-2.7x	5.57-2.2x	7.76+0.8x	7.00+2.4x	4.62-1.2x	5.80-14.2x	19.97+0.2x	19.79+2.4x	17.41+9.9x	7.49-4.3x	11.83+1.7x	10.16+2.7x	7.47
Debt-to-Equity	0.160.0x	0.170.0x	0.210.0x	0.25+0.1x	0.150.0x	0.13-0.1x	0.28+0.1x	0.19+0.1x	0.050.0x	0.060.0x	0.08-0.2x	0.25+0.1x	0.190.0x	0.15-0.5x	0.66
Asset Turnover	0.530.0x	0.58-0.3x	0.85+0.3x	0.570.0x	0.590.0x	0.62-0.3x	0.91+0.9x	0.010.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.00	N/A
FCF Margin	35.4%-13.2pp	48.6%+12.7pp	36.0%-18.2pp	54.2%+12.0pp	42.1%+4.3pp	37.8%+4.0pp	33.8%	-5247.9%	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Gross Margin	90.3%+3.0pp	82.9%-1.8pp	84.7%-0.3pp	85.9%-1.5pp	87.3%0.0pp	84.7%-1.0pp	85.0%-1.2pp	87.5%-0.4pp
Operating Margin	49.0%+4.2pp	40.5%-3.8pp	44.7%+5.1pp	45.2%+1.0pp	44.8%+17.3pp	44.3%+6.6pp	39.6%+75.8pp	44.2%-2.7pp
Net Margin	42.7%+2.5pp	34.5%-4.9pp	35.6%+1.5pp	35.5%+2.3pp	40.1%+16.5pp	39.4%+7.9pp	34.1%+64.1pp	33.2%-4.7pp
Return on Equity	6.3%-0.9pp	5.5%-2.2pp	5.7%-0.9pp	6.1%-0.6pp	7.1%+3.0pp	7.7%-1.3pp	6.6%+15.5pp	6.7%-3.4pp
Return on Assets	5.5%-0.7pp	4.8%-1.8pp	5.0%-0.7pp	5.4%-0.4pp	6.2%+2.6pp	6.6%-0.8pp	5.7%+13.1pp	5.8%-2.7pp
Current Ratio	7.10+1.0x	6.08+0.9x	6.62+1.5x	6.71+1.6x	6.14+1.1x	5.17+2.3x	5.11+1.8x	5.14+0.5x
Debt-to-Equity	0.130.0x	0.160.0x	0.140.0x	0.140.0x	0.140.0x	0.170.0x	0.170.0x	0.160.0x
Asset Turnover	0.130.0x	0.140.0x	0.140.0x	0.150.0x	0.160.0x	0.17-0.1x	0.17-0.1x	0.17-0.1x
FCF Margin	39.9%-2.6pp	29.4%-20.5pp	21.9%-34.6pp	48.6%-3.6pp	42.5%+10.2pp	49.9%-0.3pp	56.4%+12.5pp	52.3%+21.4pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Catalyst Pharmaceutical Inc. CPRX	FY2025	$589.0M	$214.3M	36.4%	$3.9B	89/100
Amicus Therapeutics, Inc FOLD	FY2025	$634.2M	-$27.1M	-4.3%	$4.5B	44/100
CG Oncology, Inc. CGON	FY2025	$4.0M	-$161.0M	N/A	$6.4B	61/100
Travere Therapeutics, Inc. TVTX	FY2025	$490.7M	-$25.5M	-5.2%	$6.2B	70/100
ImmunityBio, Inc. IBRX	FY2025	$113.3M	-$351.5M	N/A	$8.4B	41/100
Celcuity Inc. CELC	FY2025	N/A	-$177.0M	N/A	$4.1B	—

Where Catalyst Pharmaceutical Inc. Ranks

Frequently Asked Questions

What is Catalyst Pharmaceutical Inc.'s annual revenue?

Catalyst Pharmaceutical Inc. (CPRX) reported $589.0M in total revenue for fiscal year 2025. This represents a 19.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Catalyst Pharmaceutical Inc.'s revenue growing?

Catalyst Pharmaceutical Inc. (CPRX) revenue grew by 19.8% year-over-year, from $491.7M to $589.0M in fiscal year 2025.

Is Catalyst Pharmaceutical Inc. profitable?

Yes, Catalyst Pharmaceutical Inc. (CPRX) reported a net income of $214.3M in fiscal year 2025, with a net profit margin of 36.4%.

What is Catalyst Pharmaceutical Inc.'s EBITDA?

Catalyst Pharmaceutical Inc. (CPRX) had EBITDA of $295.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Catalyst Pharmaceutical Inc.'s gross margin?

Catalyst Pharmaceutical Inc. (CPRX) had a gross margin of 85.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Catalyst Pharmaceutical Inc.'s operating margin?

Catalyst Pharmaceutical Inc. (CPRX) had an operating margin of 43.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Catalyst Pharmaceutical Inc.'s net profit margin?

Catalyst Pharmaceutical Inc. (CPRX) had a net profit margin of 36.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Catalyst Pharmaceutical Inc.'s return on equity (ROE)?

Catalyst Pharmaceutical Inc. (CPRX) has a return on equity of 22.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Catalyst Pharmaceutical Inc.'s free cash flow?

Catalyst Pharmaceutical Inc. (CPRX) generated $208.6M in free cash flow during fiscal year 2025. This represents a -12.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Catalyst Pharmaceutical Inc.'s operating cash flow?

Catalyst Pharmaceutical Inc. (CPRX) generated $208.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Catalyst Pharmaceutical Inc.'s total assets?

Catalyst Pharmaceutical Inc. (CPRX) had $1.1B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Catalyst Pharmaceutical Inc.'s capital expenditures?

Catalyst Pharmaceutical Inc. (CPRX) invested $58K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Catalyst Pharmaceutical Inc. spend on research and development?

Catalyst Pharmaceutical Inc. (CPRX) invested $12.7M in research and development during fiscal year 2025.

Does Catalyst Pharmaceutical Inc. buy back shares?

Yes, Catalyst Pharmaceutical Inc. (CPRX) spent $25.3M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Catalyst Pharmaceutical Inc. have outstanding?

Catalyst Pharmaceutical Inc. (CPRX) had 122M shares outstanding as of fiscal year 2025.

What is Catalyst Pharmaceutical Inc.'s current ratio?

Catalyst Pharmaceutical Inc. (CPRX) had a current ratio of 6.08 as of fiscal year 2025, which is generally considered healthy.

What is Catalyst Pharmaceutical Inc.'s debt-to-equity ratio?

Catalyst Pharmaceutical Inc. (CPRX) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Catalyst Pharmaceutical Inc.'s return on assets (ROA)?

Catalyst Pharmaceutical Inc. (CPRX) had a return on assets of 19.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Catalyst Pharmaceutical Inc.'s Altman Z-Score?

Catalyst Pharmaceutical Inc. (CPRX) has an Altman Z-Score of 18.17, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Catalyst Pharmaceutical Inc.'s Piotroski F-Score?

Catalyst Pharmaceutical Inc. (CPRX) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Catalyst Pharmaceutical Inc.'s earnings high quality?

Catalyst Pharmaceutical Inc. (CPRX) has an earnings quality ratio of 0.97x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Catalyst Pharmaceutical Inc.?

Catalyst Pharmaceutical Inc. (CPRX) scores 89 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.